| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 5604658 | International Journal of Cardiology | 2017 | 4 Pages |
Abstract
In this pilot evaluation of the ENGAGE AF-TIMI 48 trial, treatment with edoxaban was associated with a low risk of ischemic and bleeding events during the first 30Â days post ablation.
Related Topics
Health Sciences
Medicine and Dentistry
Cardiology and Cardiovascular Medicine
Authors
Jan Steffel, Christian T. Ruff, Rose A. Hamershock, Sabina A. Murphy, Roxy Senior, Denis Roy, Hans-Joachim Lanz, Michele F. Mercuri, Elliott M. Antman, Robert P. Giugliano,